SCM
MREO

Suvretta Capital Management’s Mereo BioPharma MREO Stock Holding History

Suvretta Capital Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-75,000
Closed -$270K – 107
2024
Q2 		$270K Sell
75,000
-3,578,494
-98% -$11.6M 0.01% 94
2024
Q1 		$12.1M Sell
3,653,494
-3,717,344
-50% -$12.6M 0.45% 49
2023
Q4 		$17M Buy
7,370,838
+6,400
+0.1% +$12.2K 0.77% 39
2023
Q3 		$9.5M Hold
7,364,438
– – 0.51% 45
2023
Q2 		$9.72M Hold
7,364,438
– – 0.52% 51
2023
Q1 		$5.21M Hold
7,364,438
– – 0.22% 58
2022
Q4 		$5.52M Hold
7,364,438
– – 0.23% 56
2022
Q3 		$6.34M Sell
7,364,438
-1,777,629
-19% -$2.17M 0.26% 53
2022
Q2 		$10.2M Hold
9,142,067
– – 0.39% 55
2022
Q1 		$10.2M Hold
9,142,067
– – 0.31% 53
2021
Q4 		$14.6M Hold
9,142,067
– – 0.28% 56
2021
Q3 		$22.1M Buy
9,142,067
+492,767
+6% +$1.3M 0.37% 47
2021
Q2 		$27.4M Buy
8,649,300
+2,283,800
+36% +$7.66M 0.41% 54
2021
Q1 		$21.5M Buy
6,365,500
+3,616,501
+132% +$12.8M 0.32% 57
2020
Q4 		$9.84M Buy
+2,748,999
New +$6.89M 0.14% 62

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Suvretta Capital Management's MREO Position: Q3 2024 in Review

Suvretta Capital Management sold out of Mereo BioPharma (MREO) in Q3 2024, closing a stake of 75,000 shares — an estimated $270K sold.

Suvretta Capital Management first reported a position in MREO in Q4 2020 and held it in 15 quarters. The position peaked at $27.4M in Q2 2021. 77 funds tracked by Wall St. Rank hold MREO as of Q3 2024.

  • Suvretta Capital Management reported no remaining Mereo BioPharma position as of Q3 2024 after selling out during the quarter.
  • Suvretta Capital Management sold 75,000 Mereo BioPharma shares in Q3 2024, an estimated $270K.
  • Suvretta Capital Management first reported a position in Mereo BioPharma in Q4 2020 and held it in 15 quarters.
  • Suvretta Capital Management's Mereo BioPharma position peaked at $27.4M in Q2 2021.
  • 77 funds tracked by Wall St. Rank held Mereo BioPharma as of Q3 2024.

Based on Suvretta Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.